ライフサイエンスコーパス: acadesine

1 mized to receive either placebo (n= 2031) or acadesine (0.1 mg x kg(-1) x min(-1); n=2012) by intrave

2 participants were randomized 1:1 to receive acadesine (0.1 mg/kg per minute for 7 hours) or placebo

3 id (twice the shed blood volume) plus either acadesine (5 mg/kg bolus + 1 mg/kg x 60 min, n = 10) or

4 h) and in cardioplegia solution (placebo or acadesine; 5 microg/ml).

5 perioperative and postoperative infusion of acadesine, a first-in-class adenosine-regulating agent,

6 Acadesine also reduced the use of ventricular-assistance

7 ents undergoing CABG surgery, treatment with acadesine before and during surgery can reduce early car

8 The acadesine benefit was similar among diverse subsets, and

9 refore, we questioned whether use of the ARA acadesine-by increasing interstitial adenosine concentra

10 hrough postoperative day 4 demonstrated that acadesine decreased by 89% the number of deaths from 13.

11 high-risk patients undergoing CABG surgery, acadesine did not reduce the composite of all-cause mort

12 cacy of the adenosine regulating agent (ARA) acadesine for reducing long-term mortality among patient

13 e placebo group and 76 of 1493 (5.1%) in the acadesine group (odds ratio, 1.01 [95% CI, 0.73-1.41]).

14 transient increase in serum uric acid in the acadesine group.

15 S: The Reduction in Cardiovascular Events by Acadesine in Patients Undergoing CABG (RED-CABG) trial,

16 Acadesine is the first therapy proven to be effective fo

17 rboxamide 1-beta-d-ribofuranoside (AICAR, or acadesine) is a precursor of the monophosphate derivativ

18 randomized to receive placebo (n = 1,346) or acadesine (n = 1,352) by intravenous infusion (0.1 mg/kg

19 ar accident was not significantly reduced by acadesine (OR, 0.69; 95% Cl, 0.44-1.08; P=.10).

20 27.8% (15 of 54; placebo) to 6.5% (3 of 46; acadesine) (p = 0.006), with the principal benefit occur

21 Fluid resuscitation with acadesine produced no adverse hemodynamic consequences a

22 he placebo group to 1.4% (1 death/71 MIs) in acadesine-treated patients (P=.003).

23 Acadesine treatment, however, reduced that mortality by

24 cidence of adverse events was similar in the acadesine vs placebo groups, with the exception of a tra

25 After resuscitation with acadesine vs. vehicle, we observed the following: a) art

26 me conditions, the acute salutary effects of acadesine were probably overwhelmed by polymicrobial sep